INCYTE CORP director Otis W. Brawley received new equity awards as part of his compensation. He was granted 1,642 restricted stock units of common stock that vest in full on the first anniversary of the grant date, or earlier upon the next annual stockholder meeting or a change of control. He also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring on June 7, 2036. Following these awards, his direct common stock holdings total 12,894 shares.
Incyte Corporation reported the results of its annual shareholder meeting held on June 8, 2026. Shareholders elected eight directors, including Julian C. Baker, Jean-Jacques Bienaimé, Otis W. Brawley, and others, each receiving substantially more “for” than “against” votes.
Shareholders also approved the compensation of the company’s named executive officers on a non-binding advisory basis, with 145,851,784 votes for, 28,078,013 against, and 290,891 abstentions, plus 11,426,181 broker non-votes. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 173,072,501 votes for, 12,457,655 against, and 116,713 abstentions.
INCYTE CORP Principal Accounting Officer Tray Thomas reported an exercise-and-sale transaction in company stock. On June 4, 2026, Thomas exercised a non-qualified stock option for 2,639 shares of common stock at an exercise price of $83.83 per share, then sold 2,639 shares in an open-market transaction at $100.00 per share.
After these transactions, Thomas directly holds 21,132 shares of common stock. This total includes 15,166 shares issuable from previously reported restricted stock units that have not yet vested, indicating that a large portion of the position remains tied to equity compensation awards.
Incyte Corporation has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront. Star Therapeutics may receive up to an additional $750 million tied to sales milestones, for total potential consideration of $2.0 billion subject to customary closing adjustments.
The deal adds VGA039, a first‑in‑class investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio. The equity acquisition is expected to close in the third quarter of 2026, pending Hart‑Scott‑Rodino review, and is expected to result in an approximate $1.25 billion R&D charge in Incyte’s third‑quarter and full‑year 2026 GAAP and non‑GAAP results.
Thomas R. Tray filed a Form 144 notifying a proposed disposition of 2,639 common shares of INCY via a stock option exercise. The filing lists the sale method as Cash through the issuer on 06/04/2026. The notice also records a prior sale of 2,051 shares on 05/26/2026 for $199,664.85.
INCYTE CORP executive Pablo J. Cagnoni reported a tax-related share disposition. On the settlement of previously granted restricted stock units, 25,469 shares of common stock were automatically withheld by the company to cover tax withholding obligations at a price of $95.59 per share. After this withholding, he directly holds 240,848 shares, and this figure includes 213,078 shares tied to unvested restricted stock units and earned performance shares.
INCYTE CORP Principal Accounting Officer Tray Thomas reported an open-market sale of 2,051 shares of common stock at $97.35 per share. After this transaction, Thomas directly holds 21,132 shares. A footnote states that these holdings include 15,166 shares issuable from previously reported, unvested restricted stock units.
INCYTE CORP director Jean-Jacques Bienaimé reported routine equity compensation activity. On May 26, 2026, he exercised 15,000 shares of non-qualified stock options at an exercise price of $84.53 per share, converting an option award into common stock.
On the same date, 13,059 shares of common stock were automatically withheld by the company at $97.10 per share to cover the cost of exercising the option and related tax obligations, rather than being sold in the open market. The filing also notes previously reported restricted stock units that have not yet vested.
Morgan Stanley Smith Barney LLC Executive Financial Services reported a proposed sale of Common shares of INCY via a Form 144 filed 05/26/2026. The filing lists multiple lots tied to Restricted Stock dated 07/02/2023 and Employee Stock Purchase Plan dated 04/30/2025, with specific share line items shown.
INCYTE CORP director Paul J. Clancy completed an option exercise and share sale. On May 19, 2026, he exercised non-qualified stock options to acquire 15,000 shares of common stock at $84.53 per share and sold 15,000 shares at $94.93 per share in an open-market transaction.
After these transactions, he directly owned 23,741 shares of common stock. This figure includes 2,518 shares issuable from previously reported restricted stock units that have not yet vested.